Manufacturing, Biologic Drugs

Evaluating the Use of Continuous Chromatography

June 08, 2024

The biopharma industry is looking at continuous chromatography for sensitive molecules.

Finding a More Optimal Way for ATMPs (BIO 2024)

June 04, 2024

Pharm Tech Group looks at the challenges surrounding the development and manufacture of ATMPs in more detail with Agne Vaitkeviciene, CEO of Memel Biotech.

Seeking Excellence with CRISPR (BIO 2024)

June 04, 2024

Pharm Tech Group chats with Dr. Monika Paulė, CEO and co-founder of Caszyme about the evolution of CRISPR.

Rapid Sterility Methods for CAR T-cell Therapies

May 30, 2024

A combination of rapid sterility methods with the industry standard compendial method should ensure maximum safety.

AGC Biologics Partners with BioConnection to Offer Biopharma Drug Substance and Drug Product Development and Manufacturing

May 25, 2024

The partnership aims to provide end-to-end development and manufacturing for biopharmaceutical drug substance and drug product.

AstraZeneca Plans $1.5 Billion ADCs Facility in Singapore

May 20, 2024

The new facility will be the company’s first to offer full manufacturing processing for antibody drug conjugates.

Polysorbates: Part(icle) of the Problem?

May 05, 2024

A comparison between polysorbates and HPβCD determines the better stabilizer for biologics formulation.

Improving ADC Manufacture Means Stricter Containment Requirements and Continuous Advancement of Analytics (INTERPHEX 2024)

April 18, 2024

The improvement of ADC manufacturing now demands increased containment requirements and continually advancing analytical detection of molecules in manufacturing spaces.

WMFTS Showcases New Single-Use Solutions Designed to Optimize Fluid Management

April 16, 2024

WMFTS has launched WMArchitect, a single-use product line that offers ready-to-use single-use assemblies and custom-designed workflows for biopharma fluid management.

Lonza Forms Agreement to Manufacture Acumen Pharmaceuticals’ AD mAb Therapy

April 05, 2024

Under a collaboration agreement, Lonza will manufacture sabirnetug, Acumen Pharmaceuticals' mAb in clinical development for treating Alzheimer’s disease.